| |
|
|
|
|
ArQule, Inc.(ARQL)
|
|
|
|
|
|
|
|
|
| 123Jump Rating: |
|
Underwriters: |
Hambrecht & Quist
|
| |
|
|
CIBC Oppenheimer
|
| Status: |
|
|
Vector Securities
|
| |
| Address: |
200 Boston Avenue
Medford,
|
FiledDate: |
|
| |
|
|
|
| |
|
Filed Price Range ($): |
|
| |
|
|
|
| Telephone: |
(617) 395 - 4100 |
Filed Offer Amount ($ Million): |
$0.00 |
| |
|
|
|
| Fax: |
|
Shares Offered (Millions): |
2,000,000 |
| |
|
|
|
| Websites: |
|
Shares Outstanding (Millions): |
8,976,487 |
| |
|
|
|
| Management: |
Eric B. Gordon, Pres./CEO
|
IPO Date: |
|
| |
Joseph C. Hogan Jr., Ph.D., SVP/Chairman
|
|
|
| |
James R. Fitzgerald, Jr., CFO/VP
|
Final Offer Price ($): |
$0.00 |
| |
|
|
|
| Industry: |
Synthetic chemistry / drug development |
Final Offer Size (Millions of Shares): |
0.00 |
| |
|
|
|
| Employees: |
66 |
Final Offer Amount ($ Million): |
$0.00 |
| |
|
|
|
| Competitors: |
|
S-1 Forms: |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
- Avoid 
- Value Gap 
- Short-Term Growth
- Long-Term Growth 
- Long-Term Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product/Services Portfolio |
 |
|
|
|
|
|
|
|
|
Income Data |
| Year |
Revenues |
Costs |
Oper Income |
Taxes |
Net Income |
EPS |
| 1993
|
0.00 |
1456 |
-1454 |
0.00 |
-1465 |
0.00 |
| 1994
|
85 |
4152 |
-4067 |
0.00 |
-4206 |
0.00 |
| 1995
|
3330 |
1644 |
-1966 |
0.00 |
-2252 |
-.33 |
| 1996
|
7255 |
4739 |
-3410 |
0.00 |
-2993 |
-.4 |
| *1993 - 8 months ending Dec. 31
| |
|
|
|
|
|
|
| |
|
| |
|
|
